vaginal atrophy


Also found in: Acronyms.

vaginal atrophy

[vaj′ənəl]
a postmenopausal condition of gradually declining tissue activity in the female reproductive tract. It is caused by a cessation of follicular inhibin and estrogen secretion. This leads to decreased negative feedback on the release of follicle-stimulating hormone and luteinizing hormone by the anterior pituitary gland. Tissue effects related to estrogen deficiency include atrophy and dystrophy of the vulva and vagina, pruritus vulvae, dyspareunia, cystourethritis, ectropion, and uterovaginal prolapse.

vaginal atrophy

A condition characterised by thinning, drying, and often dyspareunia and irritation of the vagina. Vaginal atrophy most commonly occurs in menopausal and postmenopausal women, and less commonly during breast feeding or in association with reduced oestrogen production in premenopausal women.

Management
Oestrogen creams.

vaginal atrophy

Atrophic vaginitis, see there.
Mentioned in ?
References in periodicals archive ?
Last year, the Food and Drug Administration approved Osphena (ospemifene) to treat vaginal atrophy related to menopause.
Doctors revisit guidelines for treatment of menopause
Management of post-menopausal vaginal atrophy and atrophic vaginitis.
Atrophic vaginitis: concordance and interpretation of slides in the college of American Pathologists Cervicovaginal Interlaboratory Comparison Program in Gynecologic Cytopathology
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Literature review & commentary
Vaginal atrophy can also be a serious effect of the menopause, although I think we're ashamed to talk about this.
Is an estrogen skin patch for you?
A snapshot of the global therapeutic scenario for Vaginal Atrophy (Atrophic Vaginitis).
Research and Markets: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2012
18, 2015 /PRNewswire-iReach/ -- The report " Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Vaginal Atrophy Pipeline Assessment Review H1 2015 Market Research Report
com/prnh/20130307/600769 Vaginal atrophy is defined as a decrease in estrogen production.
Global PVA Drugs Market 2014-2018: Key Vendors are Actavis, Novo Nordisk, Pfizer, and Shionogi & Co
In fact, declining hormone levels can lead to vaginal atrophy -- around half of women say intercourse becomes so painful (because of thinning, fragile tissue) that they avoid it.
How to manage chronic pain
Fernard Labrie and coworkers at Laval University, Quebec, showed that intravaginal DHEA was highly and rapidly effective for the treatment of vaginal atrophy (Menopause 2009; 16:907-22), significantly improved the patients' libido and sexual function (Menopause 2009; 16:923-31) and did so with no suggestion of an increase in serum sex steroid levels (Menopause 2009; 16:897-906).
Vaginal estrogen therapy ups serum estradiol
The main assessment criteria were sexual dysfunction parameters of libido, arousal, orgasm, and dyspareunia in postmenopausal women who have vaginal atrophy.
Women's health update
Very low dosages of transvaginal oestrogens in the forms of creams, tablets and rings are effective for vaginal atrophy and urinary incontinence.
Intravaginal oestrogen and progestin administration: advantages and disadvantages
The survey showed that nearly 39 pct of post-menopausal women experience these symptoms of vaginal atrophy and 40 percent agree that it interferes with their sex life.
7 in 10 women 'feel uncomfortable' talking about vaginal dryness, pain

Medical browser ?
Full browser ?